1 of 1
Story summary
- Novo Nordisk will take legal action against Hims & Hers over a cheaper Wegovy copy.
- Novo Nordisk claims the copy is illegal, untested, and risks patient safety.
- Hims & Hers plans to sell its version for $49 for the first month, versus Wegovy at $149.
- Novo Nordisk shares fell about 7% after the announcement.
- The FDA has stated GLP-1 drugs are no longer in shortage, which may affect compounding practices.
